| Trial ID: | L0046 |
| Source ID: | NCT05965440
|
| Associated Drug: |
Impact Of Dapagliflozin On Intestinal Microbiota On Chronic Renal Failure Patients
|
| Title: |
Impact of Dapagliflozin on Intestinal Microbiota Composition and on the Metabolites Derived from the Intestinal Microbiota in Non-diabetic Chronic Renal Failure Patients
|
| Acronym: |
DAPA-GUT
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Diseases
|
| Interventions: |
DRUG: impact of Dapagliflozin on Intestinal Microbiota on chronic renal failure patients
|
| Outcome Measures: |
Primary: Alpha diversity and beta diversity size of the intestinal microbiota after 12 weeks of daily treatment with dapagliflozin compared to alfa and beta diversity size before initiation of treatment., The analysis of the microbiota by 16s sequencing of bacterial DNA will be carried out on the GenEPII platform located at the Croix Rousse hospital, Hospices Civils de Lyon (Pr Sophie JARRAUD)., Before and 12 weeks after initiation of treatment with dapagliflozin |
|
| Sponsor/Collaborators: |
Sponsor: Hospices Civils de Lyon
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
50
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC
|
| Start Date: |
2023-10-02
|
| Completion Date: |
2025-08-20
|
| Results First Posted: |
|
| Last Update Posted: |
2024-12-16
|
| Locations: |
Nephrology department, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France
|
| URL: |
https://clinicaltrials.gov/show/NCT05965440
|
